Tushar M. Patel, Mukesh C. Gohel
Tushar M. Patel1* and Mukesh C. Gohel2
1Research Scholar at Hemchandracharya North Gujarat University, Patan, Gujarat, India
L. M. College of Pharmacy, Ahmadabad, Gujarat, India.
2 Professor and Postgraduate Director, Anand Pharmacy College, Anand, Gujarat, India
Volume - 7,
Issue - 7,
Year - 2014
The aim of the present investigation was to develope extended release pellets of quetiapine fumarate. The combinations of hydrophilic (hydroxypropyl methylcellulose; HPMC K100M) and hydrophobic (Eudragit RSPO) extended release excipients were utilized for the development. The amount of HPMC K100M (X1), amount of Eudragit RSPO (X2), and amount of acidifier (anhydrous citric acid) (X3) were chosen as independent variables. These variables were optimized employing a simplex lattice design. The selected dependent variables were the cumulative percentage of quetiapine fumarate dissolved at 1 (Y1), 6 (Y2), 12 (Y3) and 20 hr (Y4). The in vitro drug release study was carried out in citrate buffer (pH 4.8) for 5 hr and thereafter the study was conducted in phosphate buffer (pH 6.6) up to 20 hours. The drug was released as per first order from the optimized formulation.
Cite this article:
Tushar M. Patel, Mukesh C. Gohel. Development of Extended Release Pellets of Quetiapine Fumarate by using HPMC and Eudragit RSPO. Research J. Pharm. and Tech. 7(7): July 2014 Page 771-775.
Tushar M. Patel, Mukesh C. Gohel. Development of Extended Release Pellets of Quetiapine Fumarate by using HPMC and Eudragit RSPO. Research J. Pharm. and Tech. 7(7): July 2014 Page 771-775. Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2014-7-7-17